Abstract: The present invention relates to a formulation comprising an endothermic cooling agent selected from the group consisting of xylitol, sorbitol, mannitol and erythritol having a heat of enthalpy between ?10 cal/g and ?100 cal/g, and one or more active agents wherein the endothermic agent is present in the formulation at an amount less than 10% w/w.

Abstract: The present invention relates to a formulation comprising an endothermic cooling agent selected from the group consisting of xylitol, sorbitol, mannitol and erythritol having a heat of enthalpy between ?10 cal/g and ?100 cal/g, and one or more active agents wherein the endothermic agent is present in the formulation at an amount less than 10% w/w.

Abstract: A pharmaceutical composition in the form of a tablet including a first portion and a second portion, wherein the first portion includes guaifenesin having an immediate release profile and a second drug having a sustained release profile, and wherein the second portion includes guaifenesin having a sustained release profile. The second drug can be in the form of a drug-resin complex. The second drug can be either an anti-tussive or a decongestant. The drug-resin complex includes a drug complexed to an ion exchange resin. The ion exchange resin can be a polystyrene sulfonate resin, polacrilex resin, polacrilin potassium, cholestyramine resin, or a colestyramine resin. The drug-resin complex can be provided with a coating, the coating thickness being selected to obtain the desired release profile. The drug-resin complex can be provided with a coating level of from 5% to 50%. The coating level can be from 10% to 35%.

Abstract: A pharmaceutical composition in the form of a tablet including a first portion and a second portion, wherein said first portion includes guaifenesin having an immediate release profile and a second drug having a sustained release profile, and wherein the second portion includes guaifenesin having a sustained release profile. The second drug can be in the form of a drug-resin complex. The second drug can be either an anti-tussive or a decongestant. The drug-resin complex includes a drug complexed to an ion exchange resin. The ion exchange resin can be a polystyrene sulfonate resin, polacrilex resin, polacrilin potassium, cholestyramine resin, or a colestyramine resin. The drug-resin complex can be provided with a coating, the coating thickness being selected to obtain the desired release profile. The drug-resin complex can be provided with a coating level of from 5% to 50%. The coating level can be from 10% to 35%.

Abstract: The present invention relates to a formulation comprising an endothermic cooling agent selected from the group consisting of xylitol, sorbitol, mannitol and erythritol having a heat of enthalpy between ?10 cal/g and ?100 cal/g, and one or more active agents wherein the endothermic agent is present in the formulation at an amount less than 10% w/w.

Abstract: A pharmaceutical composition in the form of a tablet including a first portion and a second portion, wherein said first portion includes guaifenesin having an immediate release profile and a second drug having a sustained release profile, and wherein the second portion includes guaifenesin having a sustained release profile. The second drug can be in the form of a drug-resin complex. The second drug can be either an anti-tussive or a decongestant. The drug-resin complex includes a drug complexed to an ion exchange resin. The ion exchange resin can be a polystyrene sulfonate resin, polacrilex resin, polacrilin potassium, cholestyramine resin, or a colestyramine resin. The drug-resin complex can be provided with a coating, the coating thickness being selected to obtain the desired release profile. The drug-resin complex can be provided with a coating level of from 5% to 50%. The coating level can be from 10% to 35%.

Abstract: The present invention relates to a formulation comprising an endothermic cooling agent selected from the group consisting of xylitol, sorbitol, mannitol and erythritol having a heat of enthalpy between ?10 cal/g and ?100 cal/g, and one or more active agents wherein the endothermic agent is present in the formulation at an amount less than 10% w/w.

Abstract: The invention relates to improvements in or relating to containers and in particular to an air freshening or purifying device comprising a primary container comprising an inner section and outer section each having a circumferential side wall. One of the sections has retaining means which defines at least one vapour release aperture and the other having a base. The inner section side wall is dimensioned so as to fit inside the outer section side wall, the two sections being interlockable to form the primary container. A refill container has a gel receiving surface having at least one recess for receiving a gel composition, and is located and firmly held within the primary container, the base being provided with means for attachment of the device to a surface.

Abstract: Cleaning compositions including a photocatalytic material and a sensitiser employ a photocatalytic material and a sensitiser at a locus, for example on a surface. The residue combats soils and/or undesired microorganisms at the locus. The photocatalytic material is peroxo modified titania, preferably in its anatase form, or peroxo modified titanic acid, or a mixture thereof. The compositions are preferably alkaline.

Abstract: Cleaning compositions including a photocatalytic material and a sensitiser employ a photocatalytic material and a sensitiser at a locus, for example on a surface. The residue combats soils and/or undesired microorganisms at the locus. The photocatalytic material is peroxo modified titania, preferably in its anatase form, or peroxo modified titanic acid, or a mixture thereof. The compositions are preferably alkaline.